Literature DB >> 24264833

Significant improvement following combination treatment with mefloquine and mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic peripheral blood stem cell transplantation.

Hitoshi Yoshida1, Kenji Ohshima, Jun Toda, Shinsuke Kusakabe, Hiroaki Masaie, Toshinari Yagi, Jun Ishikawa.   

Abstract

We report a case of a 40-year-old female who developed progressive multifocal leukoencephalopathy (PML), which is associated with JC virus reactivation, after allogeneic hematopoietic cell transplantation. As she had been suffering from graft-versus-host disease and lung damage after pneumocystis pneumonia, the administration of calcineurin inhibitor and steroid could not be discontinued. However, she showed a favorable improvement in clinical symptoms and imaging findings after treatment with the anti-malarial drug, mefloquine and a serotonin receptor blocker, mirtazapine. Continuation of the treatment for eight months finally led to the clearance of the JC virus from her cerebrospinal fluid. She currently shows no neurological disturbance and has resumed her daily activities. PML due to the severe immunosuppressive condition has been reported as a fatal complication after allo-SCT. Our case suggests that combination treatment with mefloquine and mirtazapine may be of great value for the treatment for PML patients in the post allo-SCT setting, although it is difficult to say whether the combination treatment alone led to improvement. Further clinical study is needed to clarify the efficacy of these drugs for the treatment of PML.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24264833     DOI: 10.1007/s12185-013-1471-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

1.  Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient.

Authors:  A Balduzzi; G Lucchini; H H Hirsch; S Basso; M Cioni; A Rovelli; A Zincone; M Grimaldi; P Corti; S Bonanomi; A Biondi; F Locatelli; E Biagi; P Comoli
Journal:  Bone Marrow Transplant       Date:  2010-10-04       Impact factor: 5.483

Review 2.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 3.  Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature.

Authors:  M A Kharfan-Dabaja; E Ayala; J Greene; A Rojiani; F R Murtagh; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2006-12-04       Impact factor: 5.483

Review 4.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

5.  Akinetic mutism caused by HIV-associated progressive multifocal leukoencephalopathy was successfully treated with mefloquine: a serial multimodal MRI Study.

Authors:  Kasane Naito; Hiroki Ueno; Mayu Sekine; Munekazu Kanemitsu; Tomohiko Ohshita; Takeshi Nakamura; Takemori Yamawaki; Masayasu Matsumoto
Journal:  Intern Med       Date:  2012-01-15       Impact factor: 1.271

6.  Mefloquine in the treatment of progressive multifocal leukoencephalopathy.

Authors:  T E Gofton; A Al-Khotani; B O'Farrell; L C Ang; R S McLachlan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-20       Impact factor: 10.154

7.  Mefloquine treatment in a patient suffering from progressive multifocal leukoencephalopathy after umbilical cord blood transplant.

Authors:  Shuji Kishida; Kozue Tanaka
Journal:  Intern Med       Date:  2010-11-15       Impact factor: 1.271

8.  Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.

Authors:  Eamonn S Molloy; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-12

9.  Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy.

Authors:  M Lanzafame; S Ferrari; E Lattuada; F Corsini; R Deganello; S Vento; E Concia
Journal:  Infez Med       Date:  2009-03

10.  Identification and characterization of mefloquine efficacy against JC virus in vitro.

Authors:  Margot Brickelmaier; Alexey Lugovskoy; Ramya Kartikeyan; Marta M Reviriego-Mendoza; Norm Allaire; Kenneth Simon; Richard J Frisque; Leonid Gorelik
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

View more
  5 in total

Review 1.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

2.  A hitherto unrecognised case of progressive multifocal leukoencephalopathy.

Authors:  Huey Kuan Tan; Chun Hong Tang
Journal:  BMJ Case Rep       Date:  2015-07-23

3.  Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy.

Authors:  Jasper Fuk-Woo Chan; Maggie Kam-Man Ma; Gavin Shueng-Wai Chan; Gary Chi-Wang Chan; Garnet Kwan-Yue Choi; Kwok-Hung Chan; Vincent Chi-Chung Cheng; Kwok-Wah Chan; Bo-Ying Choy; Kwok-Yung Yuen
Journal:  Infection       Date:  2015-05-06       Impact factor: 3.553

Review 4.  The Use of Antimalarial Drugs against Viral Infection.

Authors:  Sarah D'Alessandro; Diletta Scaccabarozzi; Lucia Signorini; Federica Perego; Denise P Ilboudo; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2020-01-08

5.  Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for Chronic Lymphocytic Leukemia.

Authors:  Yu Hashimoto; Takumi Tashiro; Ryosuke Ogawa; Kazuo Nakamichi; Masayuki Saijo; Takahisa Tateishi
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.